Bionoid Pharma Return on Equity

Bionoid Pharma (BINP) currently reports a ROE of -19.6%. That is below the sector sector average of 11.75%. Use the charts on this page to explore Bionoid Pharma's ROE history and peer comparisons.

Bionoid Pharma's ROE of -19.6% is lower than the its sector sector average of 11.75%. That is roughly 266.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Bionoid Pharma's current -19.6% should be judged against industry norms (sector average: 11.75%) and against BINP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -19.6%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.75%. From there, open related valuation or income-statement pages for Bionoid Pharma, and consider following BINP for alerts when major investors trade the stock.